Poradosu Enrique
Known title: Chief Science & Business OffCIK: 0001898147
Poradosu Enrique's purchase track record
How the stock did after each of Poradosu Enrique's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since February 4, 2022
Stock higher 6 months later
80%
3 months: 80%
Median 6-month return
+68.9%
3 months: +37.3%
Beat the S&P 500
80%
median +54.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/19/2024 | NVCT | $10K | +50.6% | +107.2% | +0.4% |
| 5/10/2024 | NVCT | $3K | +5.9% | +68.9% | +14.8% |
| 3/27/2023 | NVCT | $6K | +37.3% | +14.5% | +9.0% |
| 5/12/2022 | NVCT | $10K | -52.2% | -60.5% | +0.7% |
| 2/4/2022 | NVCT | $16K | +460.0% | +161.8% | -7.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NVCT | ▲ Buy | Grant | 150,000 | $0 | 1/6/2026 | View on chart |
| NVCT | ▲ Buy | Grant | 150,000 | $0 | 1/2/2025 | View on chart |
| NVCT | ▲ Buy | Open Market | 2,000 | $10K | 11/19/2024 | View on chart |
| NVCT | ▲ Buy | Open Market | 500 | $3K | 5/10/2024 | View on chart |
| NVCT | ▲ Buy | Grant | 130,000 | $0 | 1/3/2024 | View on chart |
| NVCT | ▲ Buy | Open Market | 500 | $6K | 3/27/2023 | View on chart |
| NVCT | ▲ Buy | Grant | 115,000 | $0 | 1/12/2023 | View on chart |
| NVCT | ▲ Buy | Open Market | 370 | $5K | 5/12/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 300 | $5K | 5/12/2022 | View on chart |
| NVCT | ▲ Buy | Grant | 60,000 | $0 | 4/1/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 800 | $3K | 2/7/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 3,800 | $13K | 2/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Nuvectis Pharma to speak at Maxim Growth Summit 2026
Nuvectis Pharma announced it will participate in the Maxim Growth Summit 2026. This corporate event provides an opportunity for the company to share updates with investors and analysts. Such appearances are standard for public companies seeking to maintain visibility in the market.
Nuvectis Pharma to speak at Maxim Growth Summit 2026. Nuvectis Pharma announced it will participate in the Maxim Growth Summit 2026. This corporate event provides an opportunity for the company to share updates with investors and analysts. Such appearances are standard for public companies seeking to maintain visibility in the market.